Even though the significance of ERβ is less clarified in breast cancer progression than its isoform, ERα, probably due to the existence of several alternatively spliced ERβ variants; however, the potential of ERβ targeting in aggressive breast cancer subtypes, as TNBC, has gained attention over the years (49). Here, ESR2 is linked to breast cancer.